Improving the lives of Canadian children and youth with rare diseases
Improving the lives of Canadian children and youth with rare diseases
Improving the lives of Canadian children and youth with rare diseases
Improving the lives of Canadian children and youth with rare diseases
Improving the lives of Canadian children and youth with rare diseases
Improving the lives of Canadian children and youth with rare diseases
New Study

On March 1, the Canadian Paediatric Surveillance Program (CPSP) began a new study on Congenital Zika syndrome in infants in Canada following the rising concerns and strong scientific consensus that Zika virus is implicated in congenital abnormalities.  A related CPSP study on severe microcephaly was launched nearly a year ago to look at cases of severe microcephaly in Canada from all causes. This new study will focus on a wide range of congenital abnormalities that have been described in infants born to mothers infected with Zika virus.  For more information and to report a case, refer to the protocol and case definition.

ADR Tips

Find out timely tips on adverse drug reactions reported to the CPSP and Health Canada.

CPSP studies

The CPSP facilitates studies in a variety of fields, such as infectious diseases, congenital and genetic diseases, injury prevention and mental health. View lists of current studies and concluded studies.

Annual Results

Results pertaining to studies and surveys are published annually. Click here for CPSP Results from 1999.

Electronic Reporting Option

Sign up for monthly electronic reporting today. The process is quick and simple – a hyperlink is sent to you each month and no log-in and password are required.

Sign Up Now

The Canadian Paediatric Surveillance Program

The Canadian Paediatric Surveillance Program (CPSP) contributes to the improvement of the health of children and youth in Canada by national surveillance and research into childhood disorders that are high in disability, morbidity and economic costs to society, despite their low frequency.  Read More.